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Abstract
Background: Fulminant hepatic failure (FHF) is clinical syndrome with very poor prognosis and high mortality there
is urgent need for the development of safe and non-toxic hepatoprotective agents for the adequate management
of hepatitis. Hepatoprotective effect of the Lepidium sativum ethanolic extract (LSEE) was assessed by D-galactosamine-
induced/lipopolysaccharide (400 mg/kg and 30 μg/kg) liver damage model in rats.
Methods: Hepatoprotective activity of LSEE (150 and 300 mg/kg) and silymarin on D-GalN/LPS induced FHF in rat was
assessed using several liver function enzyme parameters. Antioxidant properties as antioxidant stress enzymes were
assessed in hepatic Liver as well as mRNA expression of cytokines genes such as TNF-α, IL-6, and IL-10 and stress
related genes iNOS and HO-1 were determined by RT-PCR. Protein expression of apoptotic genes were evaluated
through western blot. MPO and NF-κB DNA-binding activity was analyzed by ELISA. The magnitude of hepatic
impairment was investigated through histopathological evaluation.
Results: Marked amelioration of hepatic injuries by attenuation of serum and lipid peroxidation has been observed as
comparable with silymarin (25 mg/kg p.o). D-GalN/LPS induced significant decrease in oxidative stress markers protein
level, and albumin. LSEE significantly down-regulated the D-GalN/LPS induced pro-inflammatory cytokines TNFα and
IL-6 mRNA expression in dose dependent fashion about 0.47 and 0.26 fold and up-regulates the IL-10 by 1.9 and 2.8
fold, respectively. While encourages hepatoprotective activity by down-regulating mRNA expression of iNOS and HO-1.
MPO activity and NF-κB DNA-binding effect significantly increased and was mitigated by LSEE in a dose-dependent
style as paralleled with silymarin.
Conclusion: Our data suggests that pretreatment of LSEE down regulates the caspase 3 and up-regulates the BCl2
protein expression. The above findings revealed that Lepidium sativum has significant hepatoprotective activity.
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Background
Fulminant hepatic failure (FHF), a severe disease with very
low prognosis and high mortality is caused by bacteria,
hepatitis virus, alcohol, toxic drugs and is characterized by
massive hepatocytes necrosis [1]. There is lack of active
therapies with high mortality (80–90%) detected in pa-
tients [2]. The general agreement among hematologist
there is serious concern for finding out a range of effective
medicine that can be described as hepatoprotective agents.
However, various natural products of plant origin were
studied for the mitigating effect in hepatic diseases such
as phenols, lignans, coumarins, essential oils, glycosides,
alkaloids, flavonoids, carotenoids etc. have been reported
to possess mitigating hepatic effects [3–5]. Administration
of single dose of D-GalN results in dose dependent hep-
atic damage resembling viral hepatitis, with focal necrosis
and periportal inflammation. It induces hepatitis by hin-
dering the synthesis of RNA and protein via reduction in
cellular UTP uptake that tips to the hepatic parenchyma
necrosis [6, 7]. The quinones, flavones and carotenoids are
well known antioxidants that are claimed to be hepatopro-
tective were evaluated by D-GaLN/LPS hepatic damage
model [8, 9].
Proinflammatory mediators comprising TNF-α, IL-6,
IL-10, molecules play important roles [10, 11]. Oxidative
stress causes increase of ROS by triggering of iNOS-2
[12]. HO-1, GPx1 and CAT are key enzymes, which play
crucial function in shield against the oxidative stress
prompted by toxins [13, 14]. Additionally, a proof exists
NO is a major initiator of endotoxemia and inflammation
[15]. TNF-α induced apoptosis and neutrophil transmigra-
tion, serve as a crucial mediator in the development of
acute hepatic injury [16]. TNF-α is effective in patients
with FHF. Furthermore, regarding the regulation of
TNF-α, NF-κB plays crucial role situated in cytoplasm
in inactive state then enters the nucleus which triggers
transcription of TNF-α on LPS induction [17].
Natural medicinal products might offer a natural key
to hepatoprotective effect against xenobiotic/drug [18].
Lepidium sativum L. (Brassicaceae) is medicinal plant
origin to Egypt and Middle East, now cultivated in whole
World. Lepidium sativum L used as remedy for inflamma-
tory diseases, such as diabetes, arthritis, traumatic injuries,
and hepatitis in traditional medicine [19, 20]. Lepidium
sativum L. extract is reported to have various in vitro bio-
logical effects including antioxidant, anti-inflammatory,
antidiarrheal, antimicrobial, antispasmodic and hepato-
protective action against oxidative damage and therefore,
have a great potential for use as herbal hepatoprotective
or dietary supplements [21, 22]. Literature on phytochem-
ical investigations of Lepidium sativum L. revealed the
presence of benzyl isothiocyanate, flavonoids, tannins, tri-
terpens, alkaloids, sterols, glucosinolates [20, 23] which
were reported to have, antioxidant, anti-inflammatory,
analgesic activities and hepatoprotective properties
[24–26]. The extensive literature survey showed that
no mechanistic hepatoprotective studies had been car-
ried out on this herb. The present research manuscript
describes the Efficacy of Lepidium sativum extract in
the amelioration of D-GalN/LPS induced liver injury
and oxidative damage in animal model.
Methods
Plant materials and chemicals
Lepidium sativum L seeds were procured from a local mar-
ket in Riyadh, Saudi Arabia. The seeds of Lepidium sativum
were identified by Taxonomist in the college of pharmacy,
King Saud University, Riyadh. A voucher specimen (32657)
was deposited at the Herbarium of the College of Phar-
macy, King Saud University, Riyadh, Saudi Arabia. The
seeds were washed with double distilled water, de-shelled
and dried and ground using pestle and mortar before ex-
traction. The seeds were allowed to dry under the sunlight
for two days. The seeds were then crushed and passed
through a mesh #80 to get the fine powder and stored
in dark containers free from moisture before experi-
ments. Silymarin (99%) (Standard drug) and D-GalN/LPS
(extracted from Escherichia coli) were purchased from
Sigma chemicals. All chemicals and reagents used were
of analytical grade and were purchased from Panrec
Chemicals.
Preparation of seed extracts
The extract of Lepidium sativum seeds was obtained by
complete extraction using the Soxhlet extractor. 200 g of
powdered seed sample was put into a porous thimble
and placed in a Soxhlet extractor, using ethanol as extract-
ing solvent for 8 h. The extract was obtained under re-
duced temperature, pressure and refluxing at 80 °C to
remove the excess solvent from the extract. The extract
was then stored in refrigerator for subsequent phytochem-
ical analyses. The total yield obtained was 13.4% w/w.
Phytochemical evaluation of LSEE
The preliminary screening of LSEE was carried out by
gas chromatography-mass spectrometry (GC-MS) at the
College of Pharmacy Research Center, King Saud Uni-
versity, Riyadh, Saudi Arabia, to study the phytochemical
components present in LSEE. The extracts obtained from
Soxhlet were filtered through Whatmann filter paper. The
filtrate was concentrated by rotary evaporator (Büchi).
The GC-MS analysis of extract was performed in a Perkin
Elmer (USA), Clarus 600 gas chromatography linked to a
mass spectrometer (Turbomass). The GC-MS conditions
were kept same as per our previous report [27]. Briefly, an
aliquot of 2 μL of extract was injected into the Elite -5MS
column of 30 m, 0.25 mm film thickness, 0.25 μm internal
diameters. Initial oven temperature of 30 °C for 2 min,
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increasing to 150 °C at a rate of 30 °C for 5 min and then
again increases to 300 at the rate of 5 °C for 5 min. The
injector temperature was maintained at 280 °C. The
interface temperature was 220 °C and the electron en-
ergy used was 70ev. Helium was used as a mobile phase
at a flow rate of 1.0 mL/min. Mass spectral detection
was carried out in electron ionization mode by scanning
at 40 to 600 (m/z). Finally, unknown compounds were
identified by comparing the spectra with that of the
National Institute of Standard and Technology library.




Two month old Wistar male rats (180–205 g) were used
for the investigation. Animals were kept at random and
assigned to groups of 6 animals each in standard plastic
animal cages with husk bedding. The animals were kept
at 25 ± 2 °C with 12 h light and dark cycle. The rats were
fed on standard pallet diet and provided free access of
water ad libitum. Animals were maintained in accordance
with the recommendations of the ‘Guide for the Care and
Use of Laboratory Animals’ approved by institutional
animal ethics committee of College of Pharmacy, King
Saud University, Riyadh, Saudi Arabia (Clearance No.
05763–891; January 6, 2014).
Acute toxicity
The acute oral toxicity study was conducted using the
limit test procedure according to OECD test guidelines
on acute oral toxicity test 401 [28]. The total of 6 rats of
either sex were used in the investigation. LSEE was sus-
pended in distilled water and 2 ml was administered to
rats at a single dose (2000 mg/kg b.w) by gastric gavage.
The rats were not fed for 3 h following administration.
The rats were observed uninterruptedly for 1 h and then
half hourly for 4 h for any major behavioral change and
general motor signs like writhing, convulsion, response
to tail pinching, gnawing, pupil size, fecal output, feeding
activities, etc., and additionally up to 72 h for any mortal-
ity. The significant behavioral changes and mortality was
observed (data not shown).
Experimental procedure
Animals were arbitrarily divided into five groups of six
animals each. Group I received normal saline for 14 days
and served as normal control. Group II received normal
saline (1 ml/kg, p.o.) for 14 days and served as toxic
control. Groups III and IV were prophylactically treated
with plant extract at a dose of 150 mg/kg p.o. and
300 mg/kg p.o each, respectively. Groups V served as posi-
tive control and were prophylactically treated with sily-
marin (50 mg/kg, p.o.) for 14 days. On 15th day the groups
II, III, IV and V, received D-GalN/LPS (400 mg/kg and
30 μg/kg, i.p.) [29]. After 24 h of D-GalN induced hepato-
toxicity, the blood was withdrawn from retro orbital
plexus under anesthesia in tubes containing di-sodium
EDTA. Plasma was separated by centrifugation at 2500 × g
for 10 min and was transferred to pre-labeled eppendrof
tubes for various biochemical parameters. Straightaway,
after blood withdrawal all the groups were sacrificed and
liver tissue were collected for histopathological and bio-
chemical assessments. Liver samples were washed with
chilled normal saline, and 10% (w/v) liver homogenates
were prepared in ice cold 0.15 M KCl solution using
motor driven Teflon pestle.
Determination of serum and liver homogenate
biochemical parameters
Different biochemical parameters like ALT, AST [30, 31],
ALP [32], γGGT [32]. Total protein [33], bilirubin and
albumin, respectively were estimated in serum. TBARS,
GSH [34], SOD [35], CAT [36], respectively were estimated
in homogenized liver tissue. MPO level was evaluated by
calculating the H2O2-dependent oxidation of o-dianizidine
using MPO assay kit (ab105136) [37].
Assessment of nitric oxide level
Nitric oxide was assessed by ratio of its stable metabolites,
nitrite/nitrate. Nitric oxide levels were evaluated by Griess’
method [38].
RNA isolation and quantification
Hepatic samples were used for total RNA isolation by
Trizol reagent (Life Technologies). The total RNA was
transcribed to cDNA by using high capacity cDNA reverse
transcription kit of (Applied Biosystems). Quantitative
analysis of cytokines and stress genes was performed by
real time PCR by exposing the resulting cDNA to PCR
amplification using 96-well optical reaction plates in the
ABI Prism 7500 System (Applied Biosystems). Rat primers
for TNF-α, IL-6, IL-10, HO-1, iNOS-2, and β-ACTIN
gene [27] according to the manufacturer’s protocol. Fold
variations paralleled to the controls were then evaluated
by 2 −ΔΔCt. The fold change in the level of mRNA be-
tween treated and untreated groups were corrected by the
levels of β-ACTIN. All reactions were run in duplicate.
Preparation of nuclear and total protein extracts
Frozen hepatic tissue from different experimental groups
was homogenized in ice-cold RIPA buffer comprising 1%
protease inhibitor cocktail (Sigma-Aldrich) to get total
protein extracts. After being centrifuged at 13,000 g for
20 min at 4 °C, the supernatant was collected and
used for analysis of caspase-3, Bcl-2 and β-actin ex-
pression. Similarly, nuclear extracts were prepared by
using NE-PER nuclear and cytoplasmic extraction kit
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(Pierce Biotechnology) containing 1% protease inhibitor
cocktail (Sigma-Aldrich) according to the company’s
protocol and used for analysis of NF-κB (p65) protein
expression as well as NF-κB-DNA binding assay. The
protein contents were measured by using lowery method
against BSA as reference. Bands were visualized using
Luminata™ Western Chemiluminescent HRP Substrates
(Millipore, Billerica, MA, USA) and a densitometric
analysis of the immunoblots was performed using LI-COR
C-DiGit Blot Scanners (Lincoln, NE, USA).
Analysis of NF-κB (p65) activation by ELISA
NF-κB DNA-binding activity was analyzed consuming the
NF-κB(p65) transcription factor ELISA assay kit. (Cayman
Chemical Company). Briefly, nuclear extracts were incu-
bated in the oligonucleotide-coated wells where the oligo-
nucleotide sequence contains the NF-κB response element
consensus-binding site. After washing, samples were incu-
bated by adding specific antibody directed against NF-κB
(p65). HRP conjugated secondary antibody was added to
give sensitive spectrometric readout at 450 nm.
Histopathological studies
Hepatic tissues were removed instantly, sliced and washed
in saline. Liver pieces were immersed in 10% formalin for
histopathological studies. Tissue were processed and
embedded in paraffin wax. Sections were taken and
stained with hematoxylin and eosin and observed under
microscope.
Statistical data analysis
Results are expressed as mean ± SEM. Total variation
present in a set of data was estimated by one-way analysis




The GC-MS analysis of Lepidium sativum extract revealed
the presence of 48 phytochemical constituents that could
contribute to the medicinal activity of the plant. Among
the 48 phytochemical constituents identified in the extract
are glucosinolates such as benzyl isothiocyanate, benze-
neacetonitrile and phenolic content most prominent
(Additional file 1 attached).
Protective effect of LSEE on D-GalN/LPS induced
hepatotoxicity
Preliminary studies on LSEE showed no toxicity in rat
provided with dose up to 2000 mg/kg b.w. Therefore, for
further studies 150 and 300 mg/kg b.w oral doses of ex-
tract have been selected (Additional file 2).
Assessment of biochemical markers
A significant increase in serum biomarkers AST, ALT,
ALP, γ-GT and bilirubin level was observed in animals
administered with D-GalN/LPS, which is indicative of
hepatic injuries. LSEE at a dose of 150 and 300 mg/kg
p.o. pretreatment for 7 days reduced the levels of above
mentioned parameters (P <0.05, P < 0.01, and P < 0.001)
in groups III and IV. Moreover, silymarin (group V) pre-
treatment produced highly significant reduction (P < 0.001)
in serum AST, ALT, ALP, γ-GT and bilirubin level. The
amelioration of D-GalN/LPS induced hepatic injuries by
LSEE is comparable with silymarin (Table 1).
Assessment of oxidative stress
Role of LSEE on the Level of GSH, SOD, CATand D-GalN/
LPS intoxicated rats (group II) showed a significant reduc-
tion of GSH, SOD, CAT and total protein content indicative
of an increase in protein metabolism whereas there was a
dose dependent increase in GSH, SOD, CAT and total
protein content significantly in groups III and IV (LSEE
150 and 300 mg/kg +D-GalN/LPS). Silymarin pretreatment
(group V) produced highly significant increase in GSH
(P < 0.001) (Table 1).
Assessment of antioxidant activity
The degree of lipid peroxidation is assessed by the forma-
tion of thiobarbituric acid reactive substances (TBARS).
Table 1 Effect of Lepidium sativum extract on liver and oxidative stress markers in D-GalN/LPS–induced hepatotoxicity
Serum Control D-GalN/LPS Silymarin D-GalN/LPS+ LSEE 150 mg/kg D-GalN/LPS+ LSEE 300 mg/kg
AST U/L 75.80 ± 1.04 213.52 ± 2.59 93.95 ± 0.86 194.28 ± 1.32 126.25 ± 1.62
ALT U/L 33.94 ± 0.98 95.96 ± 1.21 52.39 ± 1.20 82.93 ± 1.61 60.96 ± 1.56
ALP U/L 81.09 ± 1.80 180.86 ± 3.38 94.07 ± 2.03 150.10 ± 2.58 103.76 ± 1.30
Bilurubine plasma mg/dL 0.72 ± 0.01 1.01 ± 0.01 0.69 ± 0.01 0.92 ± 0.012 0.70 ± 0.01
γ-GGT 1.26 ± 0.06 3.12 ± 0.14 1.70 ± 0.04 2.49 ± 0.04 2.01 ± 0.08
CAT U/mg 45.09 ± 1.07 20.98 ± 1.06 39.63 ± 1.63 24.43 ± 1.22 34.18 ± 1.01
GSH nmol/mg 1.17 ± 0.02 0.46 ± 0.02 0.98 ± 0.02 0.71 ± 0.01 0.86 ± 0.02
MDA nmol/minute/mg 3.20 ± 0.10 9.80 ± 0.23 3.95 ± 0.16 7.60 ± 0.18 6.36 ± 0.14
SOD U/mg protein 22.24 ± 0.41 10.53 ± 0.35 20.49 ± 0.85 17.35 ± 0.60 19.57 ± 0.54
Data presented as mean ± SEM
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There was a sharp increase in TBARS level in D-GalN/
LPS intoxicated rats (group II) indicative of oxidative
stress. The LSEE 150 and 300 mg/kg + D-GalN/LPS in-
toxicated rats (groups III and IV) showed significant
dose dependent reduction of TBARS level as compared
to D-GalN/LPS -treated rats (group II). Table 1 displayed
significant change in the antioxidant contents of TBARS
in D-GalN/LPS intoxicated rats as 6.92 ± 0.93 (P<0.001)
compared to control group. The change in TBARS level is
comparable with silymarin.
Assessment of LSEE on mRNA expression of cytokines
genes and stress gene
The hepatic level of TNF-α and IL-6 on mRNA expression
in D-GalN/LPS intoxicated rats was up-regulated approxi-
mately 3.77 and 2.2 fold higher as comparable to normal
rats (Fig. 1). In animals receiving standard drug silymarin,
hepatic expression of TNF-α and IL-6 were down regu-
lated by 0.29 and 0.54 fold as compare to D-GalN/LPS
intoxicated rats. Interestingly LSEE down regulate the
hepatic TNF α and IL-6 mRNA expression significantly
in dose dependent fashion as compare to D-GalN/LPS
intoxicated rats. In addition, treatment of rats with LSEE
for one week prior to D-GalN/LPS administration en-
hanced the mRNA expression of IL-10, as shown in Fig. 1,
which adds more proof of the anti-inflammatory effect of
LSEE in the acute phase response to D-GalN/LPS.
The up-regulation of IL-10 mRNA by LS EE indicates
its ability to down-regulate the inflammatory cytokine.
The hepatic level of iNOS-2 on mRNA expression in
D-GalN/LPS intoxicated rats was approximately 6.04-
fold higher than that of normal rats. There is a dose
dependent significant down-regulation in rat groups
previously treated with LS EE (150 and 300 mg/kg),
silymarin + D-GalN/LPS (Fig. 2). This is about 0.47 and
0.26 down regulation in LSEE+ D-GalN/LPS rats. While
silymarin and D-GalN/LPS rats showed 0.22 fold down
regulation of iNOS2 mRNA in rat’s liver and this closely
correlates with nitrites levels measured in various groups
(Fig. 2). This further indicates that LSEE and silymarin
have anti-inflammatory activities. The degree of heme
catabolism, as shown in Table 1, illustrated consider-
ably high levels of bilirubin in serum of D-GalN/LPS
-intoxicated rats as compared to the control group. The
same inclination is witnessed in the inducible HO-1 on
mRNA expressions which were significantly increased
8.9 -fold (P ≤ 0.01) in D-GalN/LPS group compared to
control (Fig. 2). On the other hand, control did not ex-
ercise any significant changes in HO-1 on mRNA ex-
pressions LSEE and silymarin significantly (P ≤0.01)
down regulate the levels of HO-1 on mRNA expression
by 4.87, 2.45, and 1.8 fold in groups III, IV, and V,
respectively.
Assessment of MPO Level
MPO content considerably increased after D-GalN/LPS
treatment and this boost was mitigated by LSEE in a
Fig. 1 Effect of Lepidium sativum extract on mRNA expression of
cytokines genes such tumor necrotic factor-α (TNFα), Interluekine 6
(IL-6), and Interluekine 10 (IL-10). All values represent mean ± SEM.
*p < 0.05; ANOVA, followed by Dunnett’s multiple comparision test.
*compared to GalN/LPS only group
Fig. 2 Effect of Lepidium sativum extract on mRNA expression
of cytokines genes such nitrous oxide synthase (iNOS) and
Haemoxygensae1 (HO-1). All values represent mean ± SEM. *p < 0.05;
ANOVA, followed by Dunnett’s multiple comparision test. * compared
to GalN/LPS only group
Raish et al. BMC Complementary and Alternative Medicine  (2016) 16:501 Page 5 of 11
dose-dependent fashion. MPO content is comparable
with silymarin Fig. 3a.
Assessment of LSEE D-GalN/LPS induced the activity of
NF-κB
The nuclear NF-κB level was assessed by using a NF-κB
p65 transcription factor assay method. As displayed in
Fig. 3b, in D-GalN/LPS group, NF-κB activity distinctly
enhanced compared with the control group. However,
LSEE and silymarin pretreatment vividly inhibited D-
GalN/LPS -induced NF-κB activity in a dose-dependent
fashion.
Effect of LSEE on caspase-3, and bcl-2 expression
The caspase-3, and bcl-2 protein expression was detected
12 h after D-GalN/LPS administration. There is up regula-
tion of caspase-3 and down regulation of bcl-2 expression
after D-GalN/LPS administration. LSEE treatment down
regulates the caspase-3 while up regulate the bcl-2 expres-
sion about 1.7 fold as compared to the control group
(Fig. 3c).
Histopathological observations
Findings of histopathological changes in liver due to d-
GalN/LPS are shown in Fig. 4. Histology normal control
animals liver (Group I) displayed normal Browicz-Kupffer
cells architecture with well-defined central vein, well
preserved cytoplasm with prominent nucleus (Fig. 4a).
The D-GalN/LPS treated animals (Group II) displayed
Browicz-Kupffer cells with severe toxicity described by
scattered inflammation across liver parenchyma, necrosis
around the vein, enlargement up of vascular endothelial
cells and inflammatory cell collection (Fig. 4b). Moderate
to high hepatic protection from d-GalN/LPS was achieved
in Lepidium sativum with dose of 300 mg/kg. This group
showed improved liver structure with minimal cellular
necrosis. Inflammatory changes inflicted by D-GalN/LPS
were remarkably reversed by treatment with both doses of
Lepidium sativum 150 and 300 mg/kg. They seemed to
significantly inhibit the d-GalN/LPS toxicity as shown by
the Browicz-Kupffer cells with well-preserved cytoplasm
as shown in Fig. 4c and d. Silymarin (Group V) pre-
treatment showed normalization of fatty changes, cellular
infiltration and necrosis to highly significantly prevention
of d-GalN/LPS toxicity as shown by the Browicz-Kupffer
Fig. 3 Effect of LSEE on D-GalN/LPS-induced changes in inflammatory and apoptotic markers in Liver tissues of rats. a Myeloperoxidase (MPO) (b)
Nuclear NF-κB (p65) DNA-binding activity determined by using NF-κB (p65) transcription factor ELISA assay kit. c Immunoblot analysis of apoptotic
marker cleaved caspase-3 and antiapoptotic marker Bcl-2 protein in comparison with β-actin expression was used as a loading control. All values
represent mean ± SEM. *p < 0.05; ANOVA, followed by Dunnett’s multiple comparision test. * compared to GalN/LPS only group
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cells with well-preserved cytoplasm (Fig. 4e). Furthermore,
the histological evaluation of liver tissues showed that D-
GalN/LPS caused massive fatty changes, focal central vein
congestion, and necrosis with inflammation, ballooning
formation and loss of cellular boundaries. Lepidium sati-
vum seed extract treatment improved liver histology to-
wards more normalization especially with the 300 mg/kg
dose.
Discussion
Hepatic damages inflicted by D-GalN/LPS are the well
described method of xenobiotic induced hepatotoxicity
and frequently employed models for the selection of
anti-hepatotoxic or hepatoprotective agent. There is ser-
ious necessity for the development of safe and secure he-
patoprotective agent of plant origin for the management
of hepatitis. Natural herbs which hold anti-inflammatory
and antioxidant activity has become a main focus for
exploration to mitigate tissue damages. The D-GalN/
LPS inflicted hepatic injuries are parallel to that of viral
hepatitis [39, 40]. Therefore, D-GalN/LPS assisted hep-
atic damage was designated as the experimental model.
D-GalN/LPS alter the antioxidant activity of organs, vul-
nerable to oxidative stress. Previous reports have revealed
that D-galactosamine causes shift of liver biomarker en-
zymes [41]. D-GalN/LPS is recognized to inhibit the
transcription and translation as a result of endotoxemia, it
causes fulminant hepatitis [42]. D-GalN membrane archi-
tecture is believed to be accountable for the impairment
of ionic pumps. The damage in the calcium pumps, with
subsequent upsurge in the calcium leading to cell sense
[40]. D-GalN/LPS administrations may lead to marked
elevation in hepatic markers [40].
In the present research the rise in AST, ALT, ALP, γ
GGTand bilirubin levels encouraged by D-GalN treatment
was significantly abridged by LSEE (150 and 300 mg/kg)
Fig. 4 Histopathology of liver tissues. a Liver section of normal control rat shows central vein surrounded by hepatic cord of cells (normal architecture),
b liver section of D-GalN/LPS treated rats showing massive fatty changes, focal central vein congestion, ballooning formation, necrosis with inflammation
and loss of cellular boundaries, c liver section of rats treated D-GalN/LPS and 150 mg/kg of LSEE showing mild central vein congestion (indicated by
arrow), ballooning, necrosis with sinusoidal dilatation, d liver section of rats treated D-GalN/LPS and 300 mg/kg of LSEE showing absence of ballooning,
inflammatory cells and regeneration of hepatocytes around central vein toward near normal liver architecture but slight congestion in central vein
(indicated by arrow), e liver section of rats treated D-GalN/LPS and 10 mg/kg of silymarin showing normal liver architecture
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and silymarin pre-treatment ameliorate the hepatic injuries
might be due its consequence against impairment of ionic
pumps, cell leakage and loss of membrane integrity.
D-GalN/LPS may alter the antioxidant capacity of the
organs [43]. The administration LSEE to D-GalN/LPS
intoxicated rats increases the hepatic antioxidants effect
and reduces the oxidative stress, described reduced TBARS
concentration and increase in GSH, SOD and CAT con-
tents. GSH is a strong antioxidant that shields cells from
the oxidative damages and fall in GSH pool can make cells
venerable to oxidative stress [44]. In addition, GSH and
CAT work simultaneously to counteract the oxidation of
proteins, lipids and DNA by abolishing ROS [45]. LSEE
exhibits DPPH- scavenging activity, which supplementary
endorses its antioxidant activity. D-GalN is described to
inflammatory response in liver.
The D-GalN/LPS displayed severe necrosis and inflam-
mation in hepatic parenchymal cells and around portal
track. The LSEE pretreatment attenuates the myeloperoxi-
dase (MPO) level in dose dependent manner these effects
showed that LSEE has ability to down-regulated the in-
flammation to shield against D-GalN/LPS-inflicted hep-
atic injuries. Similar effects were observed in silymarin
treated animals. Several antioxidants may possess anti-
inflammatory activity [46], therefore, evaluation of in vivo
anti-inflammatory activity of LSEE on cytokines genes
TNF-α and IL-6 mRNA expression was down regulated in
D-GalN/LPS intoxicated rats. TNF-α has a key role in the
pathogenesis of D-GalN/LPS-induced FHF and apoptosis
in liver [47]. In fact, TNF-α acts by caspase-8 and then
stimulates caspase-3, a downstream cysteine proteinase
via various apoptotic pathways [47]. Interestingly, LSEE
treatment markedly reduced TNF-α and IL-6 mRNA
expression, and at the same time, enhanced the level of
IL-10. Additionally, The liver involving oxidative stress
switch the up-regulation of HO-1 mRNA expression and
upsurge in products of heme degradation pathway
[46–48]. Heme deprivation lead to production of
biliverdin/bilirubin and carbon monoxide, the crucial me-
diators of inducible HO-1 arbitrated cellular protection,
that is why they restore homeostatic balance and dimin-
ishing inflammation via down regulation of cytokines
[48, 49]. The results of HO-1 gene expression data showed
that D-GalN/LPS increases HO-1 level, while pretreat-
ment with LSEE D-GalN/LPS rats exhibited a marked re-
duction in HO-1 mRNA expression. This clearly indicates
that LSEE has a cellular protection role as well. The iNOS
2 expression and nitrite contents were significantly
augmented following D-GalN/LPS administration, that
can be ascribed to the stated D-GalN/LPS -prompted
NO production [50]. Similarly, LSEE pretreatment had
a significantly down regulate iNOS-2 expression and ni-
trate content in D-GalN/LPS intoxicated rats furthermore,
this testified that isothiocyanates arbitrates its cellular
protection by down-regulating NO production owing to
induction of HO-1 [51].
LSEE treatment significantly attenuate nitric oxide in-
duced oxidative stress progressed to reduction in in-
flammation as well as vasoconstriction of endothelial
cells [52]. The activation and nuclear translocation of
NF-κB, in response to oxidative stress/nitrosative stress,
are the key factors in the hepatic inflammatory process
by regulating the gene expression of cytokines, chemo-
kine’s, and adhesion molecules [53, 54]. This investigation,
LSEE (150–300 mg/kg) pretreatment significantly down
regulate the nuclear NF-κB expression and NF-κBDNA
binding activities as well as cytokines (TNF-α and IL-6) in
dose dependent fashion as compared to D-GalN/LPS in-
toxicated rats. Our findings corroborate those of earlier
studies demonstrating that an up surge in NF-κB activa-
tion is also followed by an increase in the concentration of
inflammatory cytokines like TNF-α and IL-6. Apoptosis is
a noticeable feature of hepatic disease.
D-GalN/LPS liver damage model exhibited the apoptosis
[11] and [55]. The apoptotic and anti-apoptotic pro-
teins such as Bcl-2 family play key role in regulation of
apoptosis. The apoptotic hepatic damage in reaction to
D-GalN/LPS is largely TNF-α dependent [47]. Therefore,
it is expected that LSEE administration reduced the
apoptosis. We have found increase caspase 3 and de-
crease Bcl-2 protein expression in D-GalN/LPS intoxi-
cated rats leading to selective depletion of UDP in
hepatic cells. The pretreatment of LSEE significantly
down regulate the Caspase 3 and up regulate Bcl-2 pro-
tein expression in D-GalN/LPS inflicted liver leading to
suppression of apoptosis. These outcomes corroborate
previous investigations [47, 56, 57]. The probable activity of
LSEE may be due to the presence of secondary metabolites
as revealed by the GC MS data the presence 48 metabolite
such as glucosinolates (benzyl isothiocyanate, benzene
acetonitrile, benzo1-(2-benzo[b] thieny), Flavonoids
(caryophyllene, 2,12-epoxycaryophyll-5), tannins, triter-
pens (Pseduosarsasapogenin-5,20-dien), alkaloids, sterols
(ergosta-5,22-dien-3-ol, acetate, 3-chloro-5-cholestene,
cholesta-8,24-dien-3-ol). These results were similar to
previous reports [20, 23]. Which are known to have anti-
microbial, antioxidant, antinflamatory and hepatopro-
tective properties in other cruciferous plants? The
glucosinolates also known as sulforaphane exerts its ef-
fect by raising GSH (NP-SH) which indirectly by stimu-
lating the Antioxidant Response Elements (ARE) in the
5′-upstream region of the gene for the heavy subunit of
γ-glutamylcysteine synthetase [58]. Sulphophranes in-
duced HO-1 and produce bilirubin a potent antioxidant
[59]. Flavonoids such as caryophyllene a potent antioxi-
dant, antinflamatory and anti-apoptotic agent by blocking
ROS mediated MAPK activation [60]. Hexadecanoic acid
may induced apoptosis and down regulation cytokines
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such TNFα, IL-6 [61]. Natural sterols such ergosterol
peroxide significantly blocked MyD88 and VCAM-1 ex-
pression, and cytokine (IL-1β, IL-6 and TNF-α) produc-
tion in LPS-stimulated cells. It also effectively inhibited
NF-kB activation [62]. The possible activity of LSEE
may be due to the presence of glucosinolates, flavonoids
and natural sterols. These findings established that LSEE
mitigates hepatic injuries and structural damage through
the decline of oxidative stress, inflammation, and apop-
tosis in the D-GalN/LPS induced liver damage.
Conclusion
Findings of this study revealed that LSEE is effective in
prevention of D-GalN/LPS induced hepatic damage in
rats. The pretreatment with LSEE significantly prevented
the D-GalN/LPS induced up surge in liver function en-
zymes (AST, ALT, γ-GGT, ALP, total bilirubin, LDH, and
Total protein). Thus significantly mitigate the reduction of
lipid peroxidation and restored the antioxidant enzymes
and total protein to normal levels. The hepatoprotective
consequence of LSEE is attributed to down regulation cyto-
kines (TNF-α, IL-6) and stress gene (iNOS and HO-1)
mRNA expression and up regulation IL-10. Nuclear NF-κB
(p65), NF-κB-DNA binding activity, myeloperoxidase
(MPO) activity, and nitric oxide level were significantly
down regulated upon LSEE pretreatment. In addition,
The LSEE pretreatment significantly down regulate the
apoptotic proteins such as Caspase 3 however up regu-
late Bcl 2 protein expression in D-GalN/LPS inflicted
liver preventing apoptosis. LSEE pretreatment also ame-
liorated the degree of structural damage and abridged in-
flammatory infiltration in hepatic cells. These findings
established that LSEE mitigates hepatic injuries and struc-
tural damage through the decline of oxidative stress, in-
flammation, and apoptosis in the liver.
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